Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4206840 | 0.77 | SIGMAR1 (0.80) | SIGMAR1 | |
| SCHEMBL8010724 | 0.76 | SIGMAR1 (0.66) | SIGMAR1 | |
| SCHEMBL15962984 | 0.76 | AVPR1A (0.41) | SIGMAR1 | |
| SCHEMBL2214270 | 0.76 | HRH4 (0.58) | — | |
| Hydrochloric Acid SCHEMBL2882074 | 0.76 | SIGMAR1 (0.78) | SIGMAR1 | |
| SCHEMBL13519328 | 0.76 | SIGMAR1 (0.59) | SIGMAR1OPRM1OPRK1KCNH2 | |
| SCHEMBL1688152 | 0.75 | SIGMAR1 (0.56) | SIGMAR1OPRM1OPRK1KCNH2 | |
| SCHEMBL8014953 | 0.74 | SIGMAR1 (0.63) | SIGMAR1OPRM1OPRK1KCNH2 | |
| SCHEMBL8012780 | 0.74 | GRIN1 (0.66) | SIGMAR1 | |
| SCHEMBL467160 | 0.74 | GRIN1 (0.70) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170327512-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | SCRIPPS RESEARCH INST (US) | 2017-11-16 | — | — | US | disclosed |
| US-20150376198-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376198-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | AVPR2, AVPR1A, AVPR1B | SIGMAR1 364/4885DRD2 205/4885DRD4 482/4885 |
| US-20170327512-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | AVPR2, AVPR1A, AVPR1B | SIGMAR1 364/4885DRD2 205/4885DRD4 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.